Background: The study originated from the authors’ coursework in health technology assessment and rational pharmaceutical policy. Purpose: To respond to the question of whether there is a global problem of access to medications by providing differentiated backgrounds and possible solutions or mitigation strategies for boosting the population’s access to medications. Method: Thematic content analysis (TCA) was performed on paper-based data. Findings: 39 documents were included, including 22 articles, eleven technical reports, two books, one book chapter, and three websites. Drug accessibility issues affect four major categories – essential, innovative, orphan, and highly-priced medicines. Access to these medications is nevertheless hampered for several reasons, including patents; prohibitive costs; fluctuating production; market unprofitability for rare diseases; and delays in innovative treatments, even in developed countries. Conclusion: Efforts to boost drug access should target all sectors – public, private, and non-governmental – and should forge ties with pharmaceutical firms and key health care institutions.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.